Phase 1 Part-A; Phase 1 Part-B; and Phase 1 Part-C:-The incidence of adverse events (AEs); adverse reactions; serious AEs (SAEs); solicited local reactogenicity AEs; and solicited systemic reactogenicity AEsPhase 2 Part:-Geometric mean titer (GMT) of SARS-CoV-2 neutralizing antibody titer

Phase 1 Part-A; Phase 1 Part-B; and Phase 1 Part-C:-The incidence of adverse events (AEs); adverse reactions; serious AEs (SAEs); solicited local reactogenicity AEs; and solicited systemic reactogenicity AEsPhase 2 Part:-Geometric mean titer (GMT) of SARS-CoV-2 neutralizing antibody titer

Phase 1 Part:- The incidence of adverse events (AEs); adverse reactions; serious AEs (SAEs); solicited local reactogenicity AEs; and solicited systemic reactogenicity AEsPhase 2 Part:- Geometric mean titer (GMT) of virus neutralizing antibody titer at Visit 6 (Day 50)

Phase 1 Part:- The incidence of adverse events (AEs); adverse reactions; serious AEs (SAEs); solicited local reactogenicity AEs; and solicited systemic reactogenicity AEsPhase 2 Part:- Geometric mean titer (GMT) of virus neutralizing antibody titer at Visit 6 (Day 50)